Riggs Asset Management’s TherapeuticsMD TXMD Stock Holding History

Riggs Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-30	Closed	-$168	–	385
2022 Q4	$168	Buy	+30	New	+$177	﹤0.01%	321
2021 Q2	–	Sell	-3	Closed	–	–	327
2021 Q1	$0	Sell	3 -4	-57%	-$313	﹤0.01%	303
2020 Q4	$0	Buy	+7	New	+$478	﹤0.01%	299
2017 Q3	–	Sell	-200	Closed	-$53K	–	291
2017 Q2	$53K	Hold	200	–	–	0.02%	122
2017 Q1	$72K	Hold	200	–	–	0.04%	99
2016 Q4	$58K	Buy	200 +161	+413%	+$49.9K	0.03%	110
2016 Q3	$13K	Buy	+39	New	+$14.2K	0.01%	184

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSP

Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Riggs Asset Management's TXMD Position: Q1 2023 in Review

Riggs Asset Management sold out of TherapeuticsMD (TXMD) in Q1 2023, closing a stake of 30 shares — an estimated $168 sold.

Riggs Asset Management first reported a position in TXMD in Q3 2016 and held it in 7 quarters. The position peaked at $72K in Q1 2017. 41 funds tracked by Wall St. Rank hold TXMD as of Q1 2023.

Riggs Asset Management reported no remaining TherapeuticsMD position as of Q1 2023 after selling out during the quarter.
Riggs Asset Management sold 30 TherapeuticsMD shares in Q1 2023, an estimated $168.
Riggs Asset Management first reported a position in TherapeuticsMD in Q3 2016 and held it in 7 quarters.
Riggs Asset Management's TherapeuticsMD position peaked at $72K in Q1 2017.
41 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2023.

Based on Riggs Asset Management's 13F filing for Q1 2023, filed 9 May 2023.